Affimed Stock Price, News & Analysis

Affimed and NKGen Biotech have initiated patient recruitment for a phase 1/2a clinical trial (NCT05099549) to evaluate the safety and effectiveness of AFM24 combined with SNK01 NK cells in treating advanced EGFR-expressing cancers such as non-small cell lung cancer, squamous cell carcinoma, and colorectal cancer. This study follows promising preclinical data presented at the AACR-NCI-EORTC conference, showing enhanced anti-tumor activity from the combination therapy. The trial aims to determine the maximum tolerated dose of AFM24 and further explore its efficacy in cancer therapy.

Affimed N.V. (Nasdaq: AFMD) announced progress on AFM28, its novel Innate Cell Engager targeting Acute Myeloid Leukemia (AML) and related conditions. Derived from the ROCK^® platform, AFM28 binds to CD123 and CD16A, demonstrating superior activity in preclinical studies compared to traditional monoclonal antibodies. A preclinical toxicology study indicated AFM28 was well-tolerated. An IND application is anticipated in the first half of 2022, with a clinical trial expected to start in the latter half.

Affimed (Nasdaq: AFMD) announced poster presentations at the 63rd ASH Annual Meeting, focusing on AFM28 and AFM13, two of its innovative innate cell engagers (ICE^®). AFM28 targets CD123+ myeloid malignancies, showing promise for Acute Myeloid Leukemia treatment, while AFM13 maintains NK cell potency after cryopreservation. An investor event in mid-December will provide updates on AFM13's clinical development, currently under two trials for T-cell lymphoma and CD30-positive lymphomas. The first-in-human study for AFM28 is anticipated to begin in late 2022.

Affimed N.V. (Nasdaq: AFMD) announced it will release its third quarter 2021 results on November 10, 2021, followed by a conference call at 8:30 a.m. EST. The call will discuss financial results and recent corporate developments. Interested parties can join by dialing +1 (409) 220-9054 for U.S. callers or +44 (0) 8000 323836 for international participants. Affimed focuses on immuno-oncology, leveraging its proprietary ROCK® platform to target and kill tumors using patients' innate immune cells. The call will be accessible via webcast and will be archived for 30 days.

Affimed (Nasdaq: AFMD) announced the acceptance of three abstracts for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), scheduled for November 10-14, 2021. The abstracts showcase preclinical data on their innate cell engagers (ICE^®), highlighting the potential of AFM24 in enhancing tumor cell phagocytosis and improving NK cell response. Full details of the abstracts will be available on November 9, 2021.

Affimed N.V. (Nasdaq: AFMD) reported its Q2 2021 financial results, highlighting a significant revenue increase to €9.7 million, up from €2.9 million in Q2 2020, thanks to collaborations with Genentech and Roivant. As of June 30, cash reserves stood at €222.7 million, expected to fund operations into the second half of 2023. The company is making steady progress in its clinical trials for AFM13 and AFM24, with enrollment for various studies on track and promising safety data reported. However, net loss widened to €18.8 million, indicating continued investment in R&D.

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology firm, announced its participation in several investor conferences in September 2021. Notable events include the Citi’s 16th Annual BioPharma Virtual Conference on September 8, offering one-on-one meetings, and the 2021 Wells Fargo Virtual Healthcare Conference on September 9, featuring a presentation at 8:00 a.m. Eastern Time. Additional meetings will take place at the Morgan Stanley Global Healthcare Conference and Cantor Fitzgerald Virtual Global Healthcare Conference. For inquiries or to schedule meetings, contact Alex Fudukidis.

Affimed N.V. (Nasdaq: AFMD) will release its second quarter 2021 financial results on September 8, 2021, followed by a conference call at 8:30 a.m. EDT. The call aims to discuss the financial results and recent corporate developments. Interested parties can access the call via phone or webcast, with details provided for both U.S. and international callers. Affimed focuses on immuno-oncology, leveraging its proprietary ROCK® platform to develop targeted treatments against various tumors. A replay of the call will be available for 30 days post-event.

Affimed N.V. (Nasdaq: AFMD) announces significant findings regarding its innate cell engager, AFM24, targeting EGFR-expressing tumors. Preclinical data highlight AFM24’s ability to engage the innate immune system effectively, emphasizing its unique mechanism that operates independently of EGFR mutations. Notably, toxicity studies in cynomolgus monkeys revealed a favorable safety profile at doses up to 75 mg/kg. These results bolster AFM24's potential in the ongoing Phase 1/2a study for patients with advanced solid tumors, reflecting promising advancements in immuno-oncology.